Cartesian Therapeutics, Inc. (RNAC)

NGM – Real vaqt narxi. Valyuta: USD

9.42

+0.49 (5.49%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

9.42

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 4:55 PM EDT

12.06.2026

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee.

09.06.2026

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma.

09.06.2026

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene's LNP platform in patients with MG; Clinical data expected in 1H 2027 FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced a strategic licensing agreement with WestGene Biopharma Co., Ltd.

26.05.2026

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028

12.05.2026

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET.

04.05.2026

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2026, the Company issued to these employees options to purchase an aggregate of 317,200 shares of the Company's common stock with an exercise price of $6.22, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on May 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on May 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

30.04.2026

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.68 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

12.06.2026

Cartesian Therapeutics, Inc. (RNAC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Announces New Employment Inducement Grant

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces New Employment Inducement Grant

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics Announces New Employment Inducement Grants

Search stocks

Cartesian Therapeutics, Inc. (RNAC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Announces New Employment Inducement Grant

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces New Employment Inducement Grant

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics Announces New Employment Inducement Grants